Fimasartan|247257-48-3|(非马沙坦; BR-A-657)-陌孚医药/Medlife

您当前的位置：

Fimasartan (Synonyms: 非马沙坦; BR-A-657)

目录号: PL05409 纯度: ≥98%

CAS No. :247257-48-3

商品编号	规格	价格	会员价
PL05409-5mg	5mg	¥525.00	请登录
PL05409-10mg	10mg	¥875.00	请登录
PL05409-50mg	50mg	¥2590.00	请登录
PL05409-100mg	100mg	¥11090.00	请登录
PL05409-200mg	200mg	询价	询价
PL05409-500mg	500mg	询价	询价
PL05409-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1684.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Fimasartan
中文别名	非马沙坦;2-丁基-5-二甲基氨基硫代甲酰甲基-6-甲基-3-[[2'-(1H-四唑-5-基)联苯-4-基]甲基]嘧啶-4(3H)-酮;非马沙坦FiMasartan;泰地唑利;特地唑胺;特地唑胺游离碱;非马沙坦杂质
英文名称	Fimasartan
英文别名	2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethylethanethioamide;2-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one;2-(1-((2'-(2H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-methyl-6-oxo-1,6-dihydropyrimidin-5-yl)-N,N-dimethy...;2-[2-butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide;BR-A-657;Fimasartan;Fimasartan-D6;BR-A-657K;Kanarb;masartan;Fimasartan [INN];Fimasartan (INN);AK120789;P58222188P;5-Pyrimidineethanethioamide, 2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-;5-Pyrimidineethanethioamide, 2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-((2'-(2H-tetrazol-5-yl)
Cas No.	247257-48-3
分子式	C₂₇H₃₁N₇Os
分子量	501.65
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Fimasartan(BR-A-657) 是血管紧张素受体 AT1 非肽类拮抗剂，用于研究高血压和心力衰竭。

生物活性

Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure. IC50 value: Target: AT1 receptor antagonist in vitro: Fimasartan suppressed the expressions of inducible nitric oxide synthase (iNOS) by down-regulating its transcription, and subsequently inhibited the productions of nitric oxide (NO). In addition, fimasartan attenuated LPS-induced transcriptional and DNA-binding activities of nuclear factor-kappa B (NF-κB) and activator protein-1 (AP-1) [1]. BR-A-657 displaced [125I][Sar1 -Ile8]angiotensin II (Ang II) from its specific binding sites to AT1 subtype receptors in membrane fractions of HEK-293 cells with an IC50 of 0.16 nM [2]. in vivo: After oral administration of 240 mg fimasartan, the mean area under the plasma concentration-time curve from time zero to infinity was 2899.0 ng/ml/h in the older, which was significantly gre

性状

Solid

IC50 & Target[1][2]

AT1 Receptor

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Ryu S, et al. Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation. Biol Pharm Bull. 2013;36(3):467-74.
[2]. Chi YH, et al. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist. Biol Pharm Bull. 2013;36(7):1208-15.

溶解度数据	In Vitro: DMSO : ≥ 49 mg/mL (97.68 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation